Find out what’s new in the pharmaceutical and biotech industries and how it affects you.

December 18,

PharmaBioSource Realty Represents Shire on the Sale of its Milford, MA Manufacturing Site

PharmaBioSource Realty provided exclusive marketing and real estate services to sell Shire’s biologics drug substance manufacturing site located in Milford, MA.  The Milford site was acquired by Rentschler Biopharma which will utilize the site as its U.S. contract manufacturing and development headquarters.  The transaction included a supply agreement for Rentschler to manufacture Obizur through Shire’s proprietary roller bottle process.  In addition to the acquisition of the 93,000 SF facility, Rentschler will retain approximately 100 staff employed at the site.

Read Press Release

September 28,

PharmaBioSource Represents Luitpold on the Sale of its GEM 21S® Asset

PharmaBioSource exclusively represented Luitpold’s Osteohealth Division on the sale of GEM 21S® fully synthetic growth-factor enhanced matrix to treat periodontally related defects.  GEM 21S® utilizes innovative tissue engineering principles combining a highly purified bioactive protein, rhPDGF-BB, with an osteoconductive matrix, B-TCP.  GEM 21S® is a fully synthetic, sterile injectable grafting system designed to stimulate wound healing and bone regeneration.  PharmaBioSource managed the process to divest the GEM 21S® asset to potential buyers and investors, including target identification and marketing, data room development, due diligence oversight, negotiations and closing support.  The GEM 21S® asset was acquired by Lynch Biologics in September 2018.

Read Press Release


August 7,

PharmaBioSource represents Shire on the sale of its Krems, Austria manufacturing facility to Merck Animal Health

MSD Animal Health, known as Merck Animal Health in the United States and Canada, today announced plans to purchase a new manufacturing facility in Krems an der Donau, Austria with the intention to expand its global vaccine manufacturing capacity. The facility, currently owned by Shire plc., was built in 2002 and will add to the company’s impressive global manufacturing capabilities.

Read Press Release


October 11,

PharmaBioSource serves as Advisor for the Sale of Irvine Pharma Services and Avrio Biopharmaceuticals to Nitto Denko Avecia

Nitto Denko Avecia Inc. (Avecia), today announced it has entered into a definitive agreement to acquire the assets of Irvine Pharmaceutical Services (Irvine) and Avrio Biopharmaceuticals (Avrio), both located in Irvine, CA. Irvine is a leading analytical development services provider and Avrio is a premier cGMP parenteral contract manufacturing organization. Avecia will consolidate both businesses into the newly established company, Nitto Avecia Pharma Services.

Read Press Release

Talk To Us

Whether you’re looking to streamline your business processes, buy or sell a manufacturing facility, or expedite a merger, our expert advisors are here to make it a smooth and favorable experience for you.

Representative Clients